IL318758A - Anti cancer combinations comprising chemotherapy - Google Patents

Anti cancer combinations comprising chemotherapy

Info

Publication number
IL318758A
IL318758A IL318758A IL31875825A IL318758A IL 318758 A IL318758 A IL 318758A IL 318758 A IL318758 A IL 318758A IL 31875825 A IL31875825 A IL 31875825A IL 318758 A IL318758 A IL 318758A
Authority
IL
Israel
Prior art keywords
chemotherapy
anti cancer
cancer combinations
combinations
cancer
Prior art date
Application number
IL318758A
Other languages
Hebrew (he)
Inventor
Takeyuki Nagashima
Original Assignee
Astellas Pharma Inc
Takeyuki Nagashima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Takeyuki Nagashima filed Critical Astellas Pharma Inc
Publication of IL318758A publication Critical patent/IL318758A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL318758A 2022-08-12 2023-08-11 Anti cancer combinations comprising chemotherapy IL318758A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22190142 2022-08-12
PCT/EP2023/072325 WO2024033538A1 (en) 2022-08-12 2023-08-11 Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity

Publications (1)

Publication Number Publication Date
IL318758A true IL318758A (en) 2025-04-01

Family

ID=83081692

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318758A IL318758A (en) 2022-08-12 2023-08-11 Anti cancer combinations comprising chemotherapy

Country Status (13)

Country Link
EP (1) EP4568675A1 (en)
JP (1) JP7733273B2 (en)
KR (1) KR20250044686A (en)
CN (1) CN119584969A (en)
AR (1) AR130192A1 (en)
AU (1) AU2023322690A1 (en)
CA (1) CA3264252A1 (en)
CL (1) CL2025000396A1 (en)
CO (1) CO2025002789A2 (en)
IL (1) IL318758A (en)
MX (1) MX2025001673A (en)
TW (1) TW202410899A (en)
WO (1) WO2024033538A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668696B1 (en) 2012-01-12 2024-05-29 예일 유니버시티 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
RU2738833C9 (en) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Imide modulators of proteolysis and methods for using them
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JOP20190186A1 (en) 2017-02-02 2019-08-01 Astellas Pharma Inc Quinazoline compound
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CA3102996A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
JP2021176820A (en) 2018-07-31 2021-11-11 アステラス製薬株式会社 Pharmaceutical composition comprising quinazoline compound as active ingredient
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN115803030A (en) 2020-04-06 2023-03-14 阿维纳斯企业公司 Compounds and methods for targeted degradation of KRAS
WO2022002102A1 (en) 2020-06-30 2022-01-06 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
WO2022105855A1 (en) 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022148422A1 (en) * 2021-01-08 2022-07-14 Beigene, Ltd. Bridged compounds as kras g12d inhibitor and degrader and the use thereof
US20240092803A1 (en) * 2021-01-08 2024-03-21 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
CR20230402A (en) 2021-01-19 2023-11-21 Lupin Ltd Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
EP4293025B1 (en) * 2021-02-15 2025-10-29 Astellas Pharma Inc. 4-aminoquinazoline compound
WO2022173032A1 (en) * 2021-02-15 2022-08-18 アステラス製薬株式会社 Quinazoline compound for inducing degradation of g12d-mutation kras protein
WO2023119677A1 (en) 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound

Also Published As

Publication number Publication date
EP4568675A1 (en) 2025-06-18
MX2025001673A (en) 2025-03-07
CN119584969A (en) 2025-03-07
JP7733273B2 (en) 2025-09-02
JP2025528008A (en) 2025-08-26
TW202410899A (en) 2024-03-16
AR130192A1 (en) 2024-11-13
CL2025000396A1 (en) 2025-04-21
WO2024033538A1 (en) 2024-02-15
CO2025002789A2 (en) 2025-04-28
AU2023322690A1 (en) 2025-03-20
CA3264252A1 (en) 2024-02-15
KR20250044686A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
EP3930747A4 (en) Immunotherapeutic combination for treating cancer
EP3836909A4 (en) Biomarkers for cancer therapy
GB202103080D0 (en) Cancer biomarkers
GB201818110D0 (en) Monocytes for cancer targeting
CA3254271A1 (en) Combination therapies for breast cancer
IL287734A (en) Tailored hypoimmune nanovesicular delivery systems for cancer tumors
IL291621A (en) Composite biomarker for cancer therapy
GB202205200D0 (en) Combination with chemotherapy
IL289006A (en) Combination cancer immunotherapy
GB202108237D0 (en) Cancer methods
IL318758A (en) Anti cancer combinations comprising chemotherapy
GB2580963B (en) Cancer therapies
GB201814487D0 (en) Cancer
GB201800733D0 (en) Cancer
GB202301902D0 (en) Combination therapy for cancer
HUE071473T2 (en) Miv-818/lenvatinib combination therapy for liver cancer
GB201913957D0 (en) Cancer
GB202112705D0 (en) Prostrate cancer biomarkers
GB201914096D0 (en) Cancer Biomarker
EP4031696A4 (en) PERSONALIZED CANCER IMMUNOTHERAPY
EP3865130A4 (en) New combination solution for treating chemotherapy refractory cancer
GB201901991D0 (en) Cancer
GB202309496D0 (en) Cancer therapies
EP3906930A4 (en) Rnai molecule for treating cancer
GB202000739D0 (en) Cancer